HomeCompareAXLA vs STAG

AXLA vs STAG: Dividend Comparison 2026

AXLA yields 43.67% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AXLA wins by $264.3K in total portfolio value
10 years
AXLA
AXLA
● Live price
43.67%
Share price
$4.58
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$282.6K
Annual income
$51,335.69
Full AXLA calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.06
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.70
Full STAG calculator →

Portfolio growth — AXLA vs STAG

📍 AXLA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAXLASTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AXLA + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AXLA pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AXLA
Annual income on $10K today (after 15% tax)
$3,711.79/yr
After 10yr DRIP, annual income (after tax)
$43,635.34/yr
STAG
Annual income on $10K today (after 15% tax)
$292.69/yr
After 10yr DRIP, annual income (after tax)
$393.29/yr
At 15% tax rate, AXLA beats the other by $43,242.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AXLA + STAG for your $10,000?

AXLA: 50%STAG: 50%
100% STAG50/50100% AXLA
Portfolio after 10yr
$150.5K
Annual income
$25,899.19/yr
Blended yield
17.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

AXLA
Analyst Ratings
6
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$60.00
+1210.0% upside vs current
Range: $60.00 — $60.00
Altman Z
-80.1
Piotroski
3/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.8% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AXLA buys
0
STAG buys
0
No recent congressional trades found for AXLA or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAXLASTAG
Forward yield43.67%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$282.6K$18.3K
Annual income after 10y$51,335.69$462.70
Total dividends collected$217.9K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$60.00$45.00

Year-by-year: AXLA vs STAG ($10,000, DRIP)

YearAXLA PortfolioAXLA Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$15,067$4,366.81$10,665$345.38+$4.4KAXLA
2$22,270$6,148.97$11,365$358.01+$10.9KAXLA
3$32,324$8,494.27$12,099$370.76+$20.2KAXLA
4$46,108$11,522.15$12,870$383.63+$33.2KAXLA
5$64,697$15,360.67$13,678$396.60+$51.0KAXLA
6$89,369$20,143.18$14,526$409.67+$74.8KAXLA
7$121,629$26,004.42$15,413$422.82+$106.2KAXLA
8$163,219$33,076.14$16,343$436.05+$146.9KAXLA
9$216,127$41,482.53$17,315$449.35+$198.8KAXLA
10$282,592$51,335.69$18,332$462.70+$264.3KAXLA

AXLA vs STAG: Complete Analysis 2026

AXLAStock

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Full AXLA Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this AXLA vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AXLA vs SCHDAXLA vs JEPIAXLA vs OAXLA vs KOAXLA vs MAINAXLA vs PLDAXLA vs EQRAXLA vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.